MDAI Stock Forecast & Price Target

Spectral AI is supported by a sizable, non-dilutive BARDA relationship, including about $31.7M of funding and an additional $9.7M in company-funded development costs, which strengthens the balance sheet while advancing DeepView toward approval and deployment. Its DeepView system addresses a large, under-penetrated wound care market with an estimated $3.7B TAM, targeting about 125 burn centers and roughly 5,000 trauma and ED units in the US, while clinical studies have already shown improved efficiency. The outlook is further reinforced by a recurring high-margin license model and expected commercialization leverage, with revenue modeled to reach $18.5M by 2030 and growth projected at a 110% CAGR in FY26 through FY30.

Spectral AI is fundamentally challenged by its dependence on DeepView commercialization and BARDA-related revenue, yet the company still has limited operating history, limited awareness, and reimbursement uncertainty that can slow adoption. The valuation itself underscores how execution-heavy the story is, with revenue only modeled at $18.5M in 2030 and growth assumptions tied to a 110% CAGR in FY26 through FY30, implying little margin for error. Any longer clinical or regulatory timelines, setbacks in approvals, or weaker commercial uptake could reduce revenue, while cybersecurity risk and the potential need for additional capital further weaken the fundamental outlook.